Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Murex Diagnostics is a prominent developer and manufacturer of high-quality in vitro diagnostic screening and monitoring tests for infectious diseases. The company is globally recognized for its enzyme-linked immunosorbent assay (ELISA) kits, which are essential for the detection of HIV, Hepatitis B, Hepatitis C, and other blood-borne pathogens. Its products are widely utilized by blood banks and clinical laboratories to ensure the safety of blood supplies and to provide accurate patient diagnoses. Originally operating as International Murex Technologies Corporation, the company was acquired by Abbott Laboratories in 1998. Following the acquisition, Murex's extensive portfolio and manufacturing expertise were integrated into Abbott's global diagnostics division, where the brand continues to represent precision in virology testing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Murex Diagnostics.